Jazz Pharmaceuticals (JAZZ) reported Q4 non-GAAP earnings late Tuesday of $6.60 per diluted share, up from $5.02 a year earlier.
Analysts polled by Capital IQ expected $5.81.
Revenue for the quarter ended Dec. 31 was $1.09 billion, up from $1.01 billion a year earlier.
Analysts surveyed by Capital IQ expected $1.06 billion.
For the full year 2025, the company expects diluted EPS of $22.50 to $24.00 on revenue of $4.15 billion to $4.40 billion. Analysts are looking for $22.03 and $4.32 billion, respectively.
Shares of Jazz Pharmaceuticals were down 2.6% in recent after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.